Cash flow Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 06:00:00 15/04/26 am AEST			5-day change	1st Jan Change
64.01 ^USD	+1.17%		+25.02%	+95.39%

14/04	Mizuho Boosts Price Target on Spyre Therapeutics to $84 From $53, Keeps Outperform Rating	MT
14/04	Deutsche Bank Adjusts Spyre Therapeutics PT to $88 From $55, Maintains Buy Rating	MT

d15e5f566b3fc1bc55ec6f92f.eIxKgVlDhCjXdOz8UDFI236p2MpULv-a09-d7TmYGXI.C_4L6j578kWdN5aQHWIehCr8nq0zGorinqWrnw70LCMd-DjXDwvWWYdFnw

Published financial data: SPYRE THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	18.74M	2.33M	886K	-	-
Total Revenues	18.74M	2.33M	886K	-	-
Cost of Goods Sold, Total	57.07M	58.58M	84.04M	163M	172M
Gross Profit	-38.33M	-56.25M	-83.16M	-163M	-172M
Selling General & Admin Expenses, Total	27.32M	28.53M	34.45M	45.78M	47.91M
Other Operating Expenses, Total	27.32M	28.53M	34.45M	45.78M	47.91M
Operating Income	-65.65M	-84.78M	-118M	-209M	-220M
Interest And Investment Income	111K	837K	6.15M	21.31M	24.88M
Net Interest Expenses	111K	837K	6.15M	21.31M	24.88M
Other Non Operating Income (Expenses)	-122K	-7K	-103M	-20.71M	29.46M
EBT, Excl. Unusual Items	-65.66M	-83.95M	-214M	-208M	-165M
Restructuring Charges	-	-	-10.95M	-	-
Gain (Loss) On Sale Of Assets	-	-	16.45M	-	10M
In Process R&D Expenses	-	-	-130M	-	-
EBT, Incl. Unusual Items	-65.66M	-83.95M	-339M	-208M	-155M
Income Tax Expense	141K	-136K	-26K	51K	-15K
Earnings From Continuing Operations	-65.8M	-83.82M	-339M	-208M	-155M
Net Income to Company	-65.8M	-83.82M	-339M	-208M	-155M
Net Income - (IS)	-65.8M	-83.82M	-339M	-208M	-155M
Preferred Dividend and Other Adjustments	-	-	-	-58.46M	-28.66M
Net Income to Common Incl Extra Items	-65.8M	-83.82M	-339M	-150M	-127M
Net Income to Common Excl. Extra Items	-65.8M	-83.82M	-339M	-150M	-127M
Per Share Items
Net EPS - Basic	-25.02	-24.86	-49.12	-3.18	-1.98
Basic EPS - Continuing Operations	-25.02	-24.86	-49.12	-3.18	-1.98
Basic Weighted Average Shares Outstanding	2.63M	3.37M	6.9M	47.03M	64.06M
Net EPS - Diluted	-25.02	-24.86	-49.12	-3.18	-1.98
Diluted EPS - Continuing Operations	-25.02	-24.86	-49.12	-3.18	-1.98
Diluted Weighted Average Shares Outstanding	2.63M	3.37M	6.9M	47.03M	64.06M
Normalized Basic EPS	-15.6	-15.56	-19.4	-2.76	-1.61
Normalized Diluted EPS	-15.6	-15.56	-19.4	-2.76	-1.61
Supplemental Items
EBITDA	-64.07M	-83.21M	-117M	-208M	-
EBITA	-65.65M	-84.78M	-118M	-209M	-220M
EBIT	-65.65M	-84.78M	-118M	-209M	-220M
EBITDAR	-62.56M	-81.83M	-116M	-	-
Total Revenues (As Reported)	18.74M	2.33M	886K	-	-
Effective Tax Rate - (Ratio)	-0.21	0.16	0.01	-0.02	0.01
Normalized Net Income	-41.04M	-52.47M	-134M	-130M	-103M
Supplemental Operating Expense Items
General and Administrative Expenses	27.32M	28.53M	34.45M	45.78M	47.91M
Research And Development Expense From Footnotes	57.07M	58.58M	220M	163M	172M
Net Rental Expense, Total	1.51M	1.38M	926K	-	-
Stock-Based Comp., COGS (Total)	2.72M	2.59M	14.12M	23.57M	16.27M
Stock-Based Comp., R&D Exp. (Total)	-	-	123K	-	-
Stock-Based Comp., G&A Exp. (Total)	5.32M	4.52M	11.44M	21.26M	21.34M
Stock-Based Comp., Other (Total)	-	-	1K	-	-
Total Stock-Based Compensation	8.04M	7.11M	25.68M	44.83M	37.61M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	15.14M	34.86M	189M	89.42M	85.72M
Short Term Investments	77.99M	20.85M	150M	514M	671M
Total Cash And Short Term Investments	93.13M	55.71M	339M	603M	757M
Accounts Receivable, Total	-	-	-	-	-
Other Receivables	815K	375K	-	-	3M
Total Receivables	815K	375K	-	-	3M
Prepaid Expenses	4.95M	6.17M	2.25M	5.39M	18.25M
Total Current Assets	98.89M	62.26M	342M	608M	778M
Gross Property Plant And Equipment	11.96M	11.39M	-	-	-
Accumulated Depreciation	-2.8M	-4.14M	-	-	-
Net Property Plant And Equipment	9.15M	7.25M	-	-	-
Other Long-Term Assets, Total	1.88M	1.64M	331K	10K	-
Total Assets	110M	71.14M	342M	608M	778M
Liabilities
Accounts Payable, Total	3.32M	677K	896K	666K	8.9M
Accrued Expenses, Total	13.25M	12.51M	29.69M	27.31M	26.77M
Current Portion of Leases	854K	641K	-	-	-
Unearned Revenue Current, Total	2.36M	517K	-	-	-
Other Current Liabilities	365K	314K	1.39M	26.08M	23.01M
Total Current Liabilities	20.14M	14.66M	31.98M	54.06M	58.68M
Long-Term Leases	4.62M	4M	-	-	-
Unearned Revenue Non Current	1.22M	2.18M	-	-	-
Other Non Current Liabilities	-	-	126M	36.62M	3.86M
Total Liabilities	25.98M	20.84M	158M	90.68M	62.54M
Preferred Stock Convertible	-	-	185M	156M	156M
Total Preferred Equity	-	-	185M	156M	156M
Common Stock, Total	5K	6K	10K	13K	15K
Additional Paid In Capital	426M	476M	763M	1.33B	1.69B
Retained Earnings	-342M	-426M	-764M	-972M	-1.13B
Comprehensive Income and Other	-20K	-48K	302K	180K	869K
Total Common Equity	83.94M	50.3M	-911K	362M	559M
Total Equity	83.94M	50.3M	184M	518M	715M
Total Liabilities And Equity	110M	71.14M	342M	608M	778M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.97M	2.62M	36.15M	60.28M	78.54M
ECS Total Common Shares Outstanding	1.97M	2.61M	36.06M	60.26M	78.19M
Book Value / Share	42.52	19.24	-0.03	6.01	7.15
Tangible Book Value	83.94M	50.3M	-911K	362M	559M
Tangible Book Value Per Share	42.52	19.24	-0.03	6.01	7.15
Total Debt	5.48M	4.64M	0	0	0
Net Debt	-87.65M	-51.07M	-339M	-603M	-757M
Debt Equivalent Oper. Leases	12.08M	11.06M	7.41M	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	2.82M	2.85M	-	-	-
Full Time Employees	101	69	30	65	102

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-65.8M	-83.82M	-339M	-208M	-155M
Depreciation & Amortization - CF	1.58M	1.57M	964K	-	-
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	-	-
Depreciation & Amortization, Total	1.58M	1.57M	964K	-	-
(Gain) Loss From Sale Of Asset	-	-	-15.53M	-	-10M
(Gain) Loss on Sale of Investments - (CF)	548K	-327K	-2.32M	-11.4M	-8.09M
Asset Writedown & Restructuring Costs	-	-	133M	-	-
Stock-Based Compensation (CF)	8.04M	7.11M	25.68M	44.83M	37.61M
Other Operating Activities, Total	90K	823K	103M	21.71M	-27.64M
Change In Accounts Receivable	-815K	440K	375K	-	-
Change In Accounts Payable	1.06M	-2.64M	218K	-16.21M	7.65M
Change in Unearned Revenues	3.58M	-880K	575K	-	-
Change in Other Net Operating Assets	-1.99M	-2.42M	-6.37M	11.68M	-13.58M
Cash from Operations	-53.72M	-80.14M	-99.91M	-157M	-169M
Capital Expenditure	-573K	-38K	-	-	-
Sale of Property, Plant, and Equipment	-	-	475K	-	-
Cash Acquisitions	-	-	3.04M	-	-
Sale (Purchase) of Intangible assets	-	-	15M	-	7M
Investment in Marketable and Equity Securities, Total	-22.05M	57.05M	-127M	-353M	-150M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-22.62M	57.01M	-108M	-353M	-143M
Long-Term Debt Repaid, Total	-510K	-418K	-16K	-	-
Total Debt Repaid	-510K	-418K	-16K	-	-
Issuance of Common Stock	1.9M	43.1M	84.96M	244M	314M
Issuance of Preferred Stock	-	-	282M	169M	-
Other Financing Activities, Total	-	-	-5.79M	-1.84M	-5.41M
Cash from Financing	1.39M	42.68M	361M	411M	309M
Foreign Exchange Rate Adjustments	-15K	-106K	25K	-3K	-
Net Change in Cash	-74.96M	19.44M	153M	-99.79M	-3.7M
Supplemental Items
Levered Free Cash Flow	-31.04M	-50.41M	-9.61M	-66.57M	-104M
Unlevered Free Cash Flow	-31.04M	-50.41M	-9.61M	-66.57M	-104M
Change In Net Working Capital	-946K	6.06M	-22.26M	-18.95M	11.24M
Net Debt Issued / Repaid	-510K	-418K	-16K	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-30.22	-58.53	-35.6	-27.43	-19.8
Return on Total Capital	-34.95	-73.41	-61.52	-37.15	-22.26
Return On Equity %	-58.81	-124.87	-289.17	-59.28	-25.17
Return on Common Equity	-58.81	-124.87	-1.37K	-82.84	-27.47
Margin Analysis
Gross Profit Margin %	-204.55	-2.42K	-9.39K	-	-
SG&A Margin	145.79	1.23K	3.89K	-	-
EBITDA Margin %	-341.92	-3.57K	-13.19K	-	-
EBITA Margin %	-350.33	-3.64K	-13.27K	-	-
EBIT Margin %	-350.33	-3.64K	-13.27K	-	-
Income From Continuing Operations Margin %	-351.14	-3.6K	-38.24K	-	-
Net Income Margin %	-351.14	-3.6K	-38.24K	-	-
Net Avail. For Common Margin %	-351.14	-3.6K	-38.24K	-	-
Normalized Net Income Margin	-219	-2.25K	-15.1K	-	-
Levered Free Cash Flow Margin	-165.66	-2.16K	-1.08K	-	-
Unlevered Free Cash Flow Margin	-165.66	-2.16K	-1.08K	-	-
Asset Turnover
Asset Turnover	0.14	0.03	0	-	-
Fixed Assets Turnover	1.96	0.28	-	-	-
Receivables Turnover (Average Receivables)	-	-	-	-	-
Short Term Liquidity
Current Ratio	4.91	4.25	10.68	11.26	13.25
Quick Ratio	4.66	3.83	10.61	11.16	12.94
Operating Cash Flow to Current Liabilities	-2.67	-5.47	-3.12	-2.91	-2.88
Days Sales Outstanding (Average Receivables)	-	-	-	-	-
Average Days Payable Outstanding	17.82	12.45	3.42	1.76	10.17
Long Term Solvency
Total Debt/Equity	6.53	9.23	-	-	-
Total Debt / Total Capital	6.13	8.45	-	-	-
LT Debt/Equity	5.51	7.96	-	-	-
Long-Term Debt / Total Capital	5.17	7.29	-	-	-
Total Liabilities / Total Assets	23.64	29.29	46.17	14.9	8.04
Total Debt / EBITDA	-0.09	-0.06	-	-	-
Net Debt / EBITDA	1.4	0.62	2.91	2.9	-
Total Debt / (EBITDA - Capex)	-0.09	-0.06	-	-	-
Net Debt / (EBITDA - Capex)	1.39	0.62	2.91	2.9	-
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-87.57	-61.96	-	-
Gross Profit, 1 Yr. Growth %	-35.73	46.75	47.84	95.76	5.44
EBITDA, 1 Yr. Growth %	-20.39	29.87	40.44	77.83	-
EBITA, 1 Yr. Growth %	-19.43	29.14	38.72	77.33	5.27
EBIT, 1 Yr. Growth %	-19.43	29.14	38.72	77.33	5.27
Earnings From Cont. Operations, 1 Yr. Growth %	-18.66	27.38	304.21	-38.6	-25.39
Net Income, 1 Yr. Growth %	-18.66	27.38	304.21	-38.6	-25.39
Normalized Net Income, 1 Yr. Growth %	-18.83	27.86	155.06	-2.88	-20.56
Diluted EPS Before Extra, 1 Yr. Growth %	-33.97	-0.64	97.58	-76.88	-37.88
Accounts Receivable, 1 Yr. Growth %	-	-	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-7.92	-20.82	-	-	-
Total Assets, 1 Yr. Growth %	-31.98	-35.28	380.52	77.99	27.82
Tangible Book Value, 1 Yr. Growth %	-39.97	-40.07	-101.81	-39.83K	54.54
Common Equity, 1 Yr. Growth %	-39.97	-40.07	-101.81	-39.83K	54.54
Cash From Operations, 1 Yr. Growth %	-29.11	49.2	24.66	57.55	7.52
Capital Expenditures, 1 Yr. Growth %	-86.61	-93.37	-	-	-
Levered Free Cash Flow, 1 Yr. Growth %	-38.89	62.38	-80.78	592.79	55.99
Unlevered Free Cash Flow, 1 Yr. Growth %	-38.89	62.38	-80.78	592.79	55.99
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	-78.26	-	-
Gross Profit, 2 Yr. CAGR %	-22.97	-2.88	47.29	70.12	43.67
EBITDA, 2 Yr. CAGR %	-10.46	1.68	35.05	58.03	-
EBITA, 2 Yr. CAGR %	-9.6	2	33.85	56.85	36.63
EBIT, 2 Yr. CAGR %	-9.6	2	33.85	56.85	36.63
Earnings From Cont. Operations, 2 Yr. CAGR %	-8.3	1.79	126.91	57.54	-32.32
Net Income, 2 Yr. CAGR %	-8.3	1.79	126.91	57.54	-32.32
Normalized Net Income, 2 Yr. CAGR %	-8.4	1.87	80.59	57.39	-12.16
Diluted EPS Before Extra, 2 Yr. CAGR %	-36.08	-19	40.11	-64.24	-62.11
Accounts Receivable, 2 Yr. CAGR %	-	-	-	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	13.01	-14.61	-	-	-
Total Assets, 2 Yr. CAGR %	14.96	-33.65	76.35	192.45	50.84
Tangible Book Value, 2 Yr. CAGR %	18.2	-40.02	-89.58	168.25	2.38K
Common Equity, 2 Yr. CAGR %	18.2	-40.02	-89.58	168.25	2.38K
Cash From Operations, 2 Yr. CAGR %	-9.57	2.84	36.38	40.15	30.16
Capital Expenditures, 2 Yr. CAGR %	-38.03	-90.58	-	-	-
Levered Free Cash Flow, 2 Yr. CAGR %	-10.85	-0.38	-43.98	15.38	228.74
Unlevered Free Cash Flow, 2 Yr. CAGR %	-10.85	-0.38	-43.98	15.38	228.74
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	68.92	-	-	-	-
Gross Profit, 3 Yr. CAGR %	5.3	-4.51	11.72	61.94	45.05
EBITDA, 3 Yr. CAGR %	12.36	1.36	13.24	48.03	-
EBITA, 3 Yr. CAGR %	13.03	1.81	13.01	47.01	37.33
EBIT, 3 Yr. CAGR %	13.03	1.81	13.01	47.01	37.33
Earnings From Cont. Operations, 3 Yr. CAGR %	14.06	2.31	61.19	46.77	22.8
Net Income, 3 Yr. CAGR %	14.06	2.31	61.19	46.77	22.8
Normalized Net Income, 3 Yr. CAGR %	13.97	2.37	38.33	46.86	25.32
Diluted EPS Before Extra, 3 Yr. CAGR %	-22.25	-25.95	9.04	-49.72	-57.01
Net Property, Plant and Equip., 3 Yr. CAGR %	107.94	0.37	-	-	-
Total Assets, 3 Yr. CAGR %	12.24	-5.08	28.37	76.9	121.94
Tangible Book Value, 3 Yr. CAGR %	7.58	-5.75	-81.32	62.77	123.21
Common Equity, 3 Yr. CAGR %	7.58	-5.75	-81.32	62.77	123.21
Cash From Operations, 3 Yr. CAGR %	18.61	6.85	9.65	43.1	28.3
Capital Expenditures, 3 Yr. CAGR %	10.73	-70.58	-	-	-
Levered Free Cash Flow, 3 Yr. CAGR %	22.2	8.87	-42.59	29.55	27.58
Unlevered Free Cash Flow, 3 Yr. CAGR %	22.2	8.87	-42.59	29.55	27.58
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	32.27	-14.86	-25.61	-	-
Gross Profit, 5 Yr. CAGR %	23.18	26.15	20.43	20.3	23.55
EBITDA, 5 Yr. CAGR %	24.09	24.85	20.94	21.06	-
EBITA, 5 Yr. CAGR %	24.55	25.09	20.94	21.02	21.93
EBIT, 5 Yr. CAGR %	24.55	25.09	20.94	21.02	21.93
Earnings From Cont. Operations, 5 Yr. CAGR %	24.84	25.21	50.18	21.6	13.92
Net Income, 5 Yr. CAGR %	24.84	25.21	50.18	21.6	13.92
Normalized Net Income, 5 Yr. CAGR %	24.79	25.25	37.01	21.59	15.35
Diluted EPS Before Extra, 5 Yr. CAGR %	-14.7	-11.19	-1.6	-44.65	-44.61
Net Property, Plant and Equip., 5 Yr. CAGR %	72.52	53.37	-	-	-
Total Assets, 5 Yr. CAGR %	10.39	4.87	34.48	48.88	36.92
Tangible Book Value, 5 Yr. CAGR %	5.92	-0.01	-57.72	43.22	31.95
Common Equity, 5 Yr. CAGR %	5.92	-0.01	-57.72	43.22	31.95
Cash From Operations, 5 Yr. CAGR %	23.31	26.63	25.42	19.1	17.44
Capital Expenditures, 5 Yr. CAGR %	22	-42.77	-	-	-
Levered Free Cash Flow, 5 Yr. CAGR %	28.98	26.98	-10.8	11.25	15.38
Unlevered Free Cash Flow, 5 Yr. CAGR %	28.98	26.98	-10.8	11.25	15.38